Lumiliximab

Lumiliximab
Monoclonal antibody
Type	Whole antibody
Source	Chimeric (primate/human)
Target	CD23
Clinical data
ATC code	none;
Identifiers
CAS Number	357613-86-6 ;
DrugBank	DB06162 ;
ChemSpider	none;
UNII	8Z13S29R5A;
Chemical and physical data
Formula	C2115H3252N556O673S16
Molar mass	47749.46 g·mol−1
	(what is this?) (verify)

Lumiliximab is an IgG1k monoclonal antibody that targets CD23. It acts as an immunomodulator[1] and was awarded orphan drug status and fast track designation by the FDA.[2]

It was investigated in Phase II/III clinical trials for the treatment of chronic lymphocytic leukemia.[3][4] It has also been studied for use in allergic asthma. The drug is a chimeric antibody from Macaca irus and Homo sapiens.[1]

Lumiliximab was developed by IDEC Pharmaceuticals, which was acquired by Biogen. Clinical trials for CLL were terminated in 2010, and for allergic asthma in 2007.[2] Results published from the CLL clinical trial failed to meet primary endpoints.[5]

References

"International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. 18 (3). 2004.
"Lumiliximab". Adis Insight. Springer Nature Switzerland AG.
Byrd JC, Kipps TJ, Flinn IW, Castro J, Lin TS, Wierda W, et al. (January 2010). "Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia". Blood. 115 (3): 489–95. doi:10.1182/blood-2009-08-237727. PMC 2810983. PMID 19843887.
Clinical trial number NCT00801060 for "Evaluation of Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) +/- Lumiliximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia (CLL)" at ClinicalTrials.gov
Awan FT, Hillmen P, Hellmann A, Robak T, Hughes SG, Trone D, et al. (November 2014). "A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia". British Journal of Haematology. 167 (4): 466–77. doi:10.1111/bjh.13061. PMID 25130401. S2CID 25789983.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[INN-1] "International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. 18 (3). 2004.

[adisinsight.springer.com-2] "Lumiliximab". Adis Insight. Springer Nature Switzerland AG.

[3] Byrd JC, Kipps TJ, Flinn IW, Castro J, Lin TS, Wierda W, et al. (January 2010). "Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia". Blood. 115 (3): 489–95. doi:10.1182/blood-2009-08-237727. PMC 2810983. PMID 19843887.

[4] Clinical trial number NCT00801060 for "Evaluation of Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) +/- Lumiliximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia (CLL)" at ClinicalTrials.gov

[5] Awan FT, Hillmen P, Hellmann A, Robak T, Hughes SG, Trone D, et al. (November 2014). "A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia". British Journal of Haematology. 167 (4): 466–77. doi:10.1111/bjh.13061. PMID 25130401. S2CID 25789983.